1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hemophilia Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hemophilia Market Revenue and Volume, by Type
8.1.1. Hemophilia A
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Hemophilia B
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Hemophilia C
8.1.3.1. Market Revenue and Volume Forecast
9.1. Hemophilia Market Revenue and Volume, by Treatment
9.1.1. Replacement Therapy
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Gene Therapy
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Desmopressin Therapy
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Immunotherapy
9.1.4.1. Market Revenue and Volume Forecast
10.1. Hemophilia Market Revenue and Volume, by Product
10.1.1. Coagulation Factor Concentrates
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Recombinant Factor
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Plasma-derived Factor
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. Hemophilia Market Revenue and Volume, by Route of Administration
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Subcutaneous (SC)
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Oral
11.1.3.1. Market Revenue and Volume Forecast
12.1. Hemophilia Market Revenue and Volume, by End-Use
12.1.1. Hospitals
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Specialty Clinics
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Homecare
12.1.3.1. Market Revenue and Volume Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Type
13.1.2. Market Revenue and Volume Forecast, by Treatment
13.1.3. Market Revenue and Volume Forecast, by Product
13.1.4. Market Revenue and Volume Forecast, by Route of Administration
13.1.5. Market Revenue and Volume Forecast, by End-Use
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Type
13.1.6.2. Market Revenue and Volume Forecast, by Treatment
13.1.6.3. Market Revenue and Volume Forecast, by Product
13.1.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.1.6.5. Market Revenue and Volume Forecast, by End-Use
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Type
13.1.7.2. Market Revenue and Volume Forecast, by Treatment
13.1.7.3. Market Revenue and Volume Forecast, by Product
13.1.7.4. Market Revenue and Volume Forecast, by Route of Administration
13.1.7.5. Market Revenue and Volume Forecast, by End-Use
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Type
13.2.2. Market Revenue and Volume Forecast, by Treatment
13.2.3. Market Revenue and Volume Forecast, by Product
13.2.4. Market Revenue and Volume Forecast, by Route of Administration
13.2.5. Market Revenue and Volume Forecast, by End-Use
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Type
13.2.6.2. Market Revenue and Volume Forecast, by Treatment
13.2.6.3. Market Revenue and Volume Forecast, by Product
13.2.7. Market Revenue and Volume Forecast, by Route of Administration
13.2.8. Market Revenue and Volume Forecast, by End-Use
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Type
13.2.9.2. Market Revenue and Volume Forecast, by Treatment
13.2.9.3. Market Revenue and Volume Forecast, by Product
13.2.10. Market Revenue and Volume Forecast, by Route of Administration
13.2.11. Market Revenue and Volume Forecast, by End-Use
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Type
13.2.12.2. Market Revenue and Volume Forecast, by Treatment
13.2.12.3. Market Revenue and Volume Forecast, by Product
13.2.12.4. Market Revenue and Volume Forecast, by Route of Administration
13.2.13. Market Revenue and Volume Forecast, by End-Use
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Type
13.2.14.2. Market Revenue and Volume Forecast, by Treatment
13.2.14.3. Market Revenue and Volume Forecast, by Product
13.2.14.4. Market Revenue and Volume Forecast, by Route of Administration
13.2.15. Market Revenue and Volume Forecast, by End-Use
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Type
13.3.2. Market Revenue and Volume Forecast, by Treatment
13.3.3. Market Revenue and Volume Forecast, by Product
13.3.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.5. Market Revenue and Volume Forecast, by End-Use
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Type
13.3.6.2. Market Revenue and Volume Forecast, by Treatment
13.3.6.3. Market Revenue and Volume Forecast, by Product
13.3.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.7. Market Revenue and Volume Forecast, by End-Use
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Type
13.3.8.2. Market Revenue and Volume Forecast, by Treatment
13.3.8.3. Market Revenue and Volume Forecast, by Product
13.3.8.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.9. Market Revenue and Volume Forecast, by End-Use
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Type
13.3.10.2. Market Revenue and Volume Forecast, by Treatment
13.3.10.3. Market Revenue and Volume Forecast, by Product
13.3.10.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.10.5. Market Revenue and Volume Forecast, by End-Use
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Type
13.3.11.2. Market Revenue and Volume Forecast, by Treatment
13.3.11.3. Market Revenue and Volume Forecast, by Product
13.3.11.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.11.5. Market Revenue and Volume Forecast, by End-Use
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Type
13.4.2. Market Revenue and Volume Forecast, by Treatment
13.4.3. Market Revenue and Volume Forecast, by Product
13.4.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.5. Market Revenue and Volume Forecast, by End-Use
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Type
13.4.6.2. Market Revenue and Volume Forecast, by Treatment
13.4.6.3. Market Revenue and Volume Forecast, by Product
13.4.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.7. Market Revenue and Volume Forecast, by End-Use
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Type
13.4.8.2. Market Revenue and Volume Forecast, by Treatment
13.4.8.3. Market Revenue and Volume Forecast, by Product
13.4.8.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.9. Market Revenue and Volume Forecast, by End-Use
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Type
13.4.10.2. Market Revenue and Volume Forecast, by Treatment
13.4.10.3. Market Revenue and Volume Forecast, by Product
13.4.10.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.10.5. Market Revenue and Volume Forecast, by End-Use
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Type
13.4.11.2. Market Revenue and Volume Forecast, by Treatment
13.4.11.3. Market Revenue and Volume Forecast, by Product
13.4.11.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.11.5. Market Revenue and Volume Forecast, by End-Use
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Type
13.5.2. Market Revenue and Volume Forecast, by Treatment
13.5.3. Market Revenue and Volume Forecast, by Product
13.5.4. Market Revenue and Volume Forecast, by Route of Administration
13.5.5. Market Revenue and Volume Forecast, by End-Use
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Type
13.5.6.2. Market Revenue and Volume Forecast, by Treatment
13.5.6.3. Market Revenue and Volume Forecast, by Product
13.5.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.5.7. Market Revenue and Volume Forecast, by End-Use
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Type
13.5.8.2. Market Revenue and Volume Forecast, by Treatment
13.5.8.3. Market Revenue and Volume Forecast, by Product
13.5.8.4. Market Revenue and Volume Forecast, by Route of Administration
13.5.8.5. Market Revenue and Volume Forecast, by End-Use
14.1. Bayer
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Novo Nordisk
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Pfizer
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Sanofi
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Grifols
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. CSL Behring
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Ferring Pharmaceuticals
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Baxter International
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Shire (Takeda)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Octapharma
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
